Figure 3. Mutation of the palmitoylated cysteine 1025 of EGFR in combination with Kras^G12V increases gefitinib sensitivity.

(A) NIH3T3 cells stably expressing inducible full length EGFR^WT or EGFR^C1025A or empty vector control (EV) with Kras^WT (left) or Kras^G12V (right). Immunoblotting with EGFR shows induced expression of EGFR^WT and EGFR^C1025A, and immunoblotting with HA shows expression of HA-tagged Kras^G12V. (B) Induced expression of EGFR^C1025A in NIH3T3 stably expressing Kras^G12V increased gefitinib-induced cell death. Cells were treated with doxocycline (1µg/ml) every 24 hours for 72 hours and with DMSO or 5 µM Gefitinib at 24 hours post-seeding. Cell viability was measured by Trypan Blue staining at 72 hours post-treatment (mean +/−StDev).